These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

297 related items for PubMed ID: 14704596

  • 1. Optimizing LDL-C lowering with statins.
    McKenney JM.
    Am J Ther; 2004; 11(1):54-9. PubMed ID: 14704596
    [Abstract] [Full Text] [Related]

  • 2. Managing dyslipidemia in the high-risk patient.
    Stein EA.
    Am J Cardiol; 2002 Mar 07; 89(5A):50C-57C. PubMed ID: 11900720
    [Abstract] [Full Text] [Related]

  • 3. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ, Watson KE, Talbert RL.
    J Manag Care Pharm; 2008 Oct 07; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [Abstract] [Full Text] [Related]

  • 4. A new reality: achieving cholesterol-lowering goals in clinical practice.
    Gaw A.
    Atheroscler Suppl; 2002 Apr 07; 2(4):5-8; discussion 8-11. PubMed ID: 11976071
    [Abstract] [Full Text] [Related]

  • 5. Current lipid management and low cholesterol goal attainment in common daily practice in Spain. The REALITY Study.
    García Ruiz FJ, Marín Ibáñez A, Pérez-Jiménez F, Pintó X, Nocea G, Ahumada C, Alemao E, Yin D, REALITY Study Group.
    Pharmacoeconomics; 2004 Apr 07; 22 Suppl 3():1-12. PubMed ID: 15669149
    [Abstract] [Full Text] [Related]

  • 6. Niacin as a component of combination therapy for dyslipidemia.
    Miller M.
    Mayo Clin Proc; 2003 Jun 07; 78(6):735-42. PubMed ID: 12934785
    [Abstract] [Full Text] [Related]

  • 7. Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease.
    Toth PP, Foody JM, Tomassini JE, Sajjan SG, Ramey DR, Neff DR, Tershakovec AM, Hu XH, Tunceli K.
    J Clin Lipidol; 2014 Jun 07; 8(1):107-16. PubMed ID: 24528691
    [Abstract] [Full Text] [Related]

  • 8. [Optimization of cholesterol reduction principles and clinical results of dual inhibition].
    von Hodenberg E.
    Internist (Berl); 2005 May 07; 46 Suppl 1():S18-23. PubMed ID: 15834540
    [Abstract] [Full Text] [Related]

  • 9. Pharmacotherapy of dyslipidemia.
    McKenney JM.
    Cardiovasc Drugs Ther; 2001 Sep 07; 15(5):413-22. PubMed ID: 11855660
    [Abstract] [Full Text] [Related]

  • 10. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M, Roberts A, Davies S, Rees A.
    Drugs; 2004 Sep 07; 64(11):1181-96. PubMed ID: 15161326
    [Abstract] [Full Text] [Related]

  • 11. Patterns and effectiveness of lipid-lowering therapies in a managed care environment.
    Meyer JW, Schultz JS, O'Donnell JC, Patel PA, Sasane RM.
    Value Health; 2005 Sep 07; 8(5):601-12. PubMed ID: 16176498
    [Abstract] [Full Text] [Related]

  • 12. Role of colesevelam in combination lipid-lowering therapy.
    Jones MR, Nwose OM.
    Am J Cardiovasc Drugs; 2013 Oct 07; 13(5):315-23. PubMed ID: 23913404
    [Abstract] [Full Text] [Related]

  • 13. Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety.
    Hou R, Goldberg AC.
    Endocrinol Metab Clin North Am; 2009 Mar 07; 38(1):79-97. PubMed ID: 19217513
    [Abstract] [Full Text] [Related]

  • 14. Perspectives on low-density lipoprotein cholesterol goal achievement.
    Catapano AL.
    Curr Med Res Opin; 2009 Feb 07; 25(2):431-47. PubMed ID: 19192988
    [Abstract] [Full Text] [Related]

  • 15. Improving lipid management--to titrate, combine or switch.
    Schuster H.
    Int J Clin Pract; 2004 Jul 07; 58(7):689-94. PubMed ID: 15311726
    [Abstract] [Full Text] [Related]

  • 16. Therapeutic implications of recent ATP III guidelines and the important role of combination therapy in total dyslipidemia management.
    Boden WE.
    Curr Opin Cardiol; 2003 Jul 07; 18(4):278-85. PubMed ID: 12858126
    [Abstract] [Full Text] [Related]

  • 17. 2017 Taiwan lipid guidelines for high risk patients.
    Li YH, Ueng KC, Jeng JS, Charng MJ, Lin TH, Chien KL, Wang CY, Chao TH, Liu PY, Su CH, Chien SC, Liou CW, Tang SC, Lee CC, Yu TY, Chen JW, Wu CC, Yeh HI, Writing Group of 2017 Taiwan Lipid Guidelines for High Risk Patients.
    J Formos Med Assoc; 2017 Apr 07; 116(4):217-248. PubMed ID: 28242176
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis.
    Sabatine MS, Wiviott SD, Im K, Murphy SA, Giugliano RP.
    JAMA Cardiol; 2018 Sep 01; 3(9):823-828. PubMed ID: 30073316
    [Abstract] [Full Text] [Related]

  • 19. The power of statins: aggressive lipid lowering.
    Stein EA.
    Clin Cardiol; 2003 Apr 01; 26(4 Suppl 3):III25-31. PubMed ID: 12708636
    [Abstract] [Full Text] [Related]

  • 20. LDL reduction: how low should we go and is it safe?
    Robinson JG.
    Curr Cardiol Rep; 2008 Nov 01; 10(6):481-7. PubMed ID: 18950559
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.